Brookline Capital Management Forecasts Genelux Q1 Earnings

Genelux Co. (NASDAQ:GNLX) – Equities research analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for shares of Genelux in a report released on Tuesday, March 25th. Brookline Capital Management analyst K. Dolliver expects that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS and Q4 2025 earnings at ($0.16) EPS.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Friday, April 4th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.07).

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Genelux in a report on Tuesday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $18.25.

Genelux Stock Up 1.7 %

Shares of GNLX stock opened at $3.08 on Thursday. Genelux has a 12-month low of $1.60 and a 12-month high of $6.50. The company has a 50 day moving average of $4.06 and a 200-day moving average of $3.10. The firm has a market cap of $106.38 million, a P/E ratio of -3.24 and a beta of -1.41.

Hedge Funds Weigh In On Genelux

Several large investors have recently modified their holdings of the business. Marshall Wace LLP boosted its holdings in Genelux by 51.4% in the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock worth $368,000 after buying an additional 52,958 shares during the period. Raymond James Financial Inc. bought a new position in shares of Genelux in the fourth quarter worth $41,000. LPL Financial LLC boosted its holdings in shares of Genelux by 72.3% in the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock worth $222,000 after acquiring an additional 39,516 shares during the period. Virtu Financial LLC purchased a new position in shares of Genelux in the fourth quarter valued at $25,000. Finally, LifeSteps Financial Inc. raised its stake in shares of Genelux by 11.1% during the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock valued at $205,000 after purchasing an additional 8,715 shares during the period. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.